LENZ Therapeutics (LENZ) Assets Average (2021 - 2026)

LENZ Therapeutics (LENZ) has 6 years of Assets Average data on file, last reported at $289.2 million in Q1 2026.

• Quarterly Assets Average rose 38.86% year-over-year to $289.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $289.2 million (up 38.86% YoY) and the FY2025 annual result came in at $260.6 million, up 82.43% from the prior year.
• Assets Average improved to $289.2 million in Q1 2026 per LENZ's latest filing, from $258.3 million in the prior quarter.
• Across five years, Assets Average topped out at $390.3 million in Q1 2022 and bottomed at $143.8 million in Q1 2024.
• The 5-year median for Assets Average is $258.3 million (2025), against an average of $262.0 million.
• The widest annual swing landed in 2024, when Assets Average tumbled 54.47%; it then jumped 44.79% in 2025.
• Tracing LENZ's Assets Average over 5 years: stood at $328.4 million in 2022, then plunged by 48.75% to $168.3 million in 2023, then soared by 30.51% to $219.7 million in 2024, then grew by 17.59% to $258.3 million in 2025, then rose by 11.97% to $289.2 million in 2026.
• Per Business Quant, the three latest LENZ Assets Average figures stand at $289.2 million (Q1 2026), $258.3 million (Q4 2025), and $214.0 million (Q3 2025).

Peer Comparison